CDK inhibitors in cancer therapy: what is next?
- 1 January 2008
- journal article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 29 (1), 16-21
- https://doi.org/10.1016/j.tips.2007.10.012
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Cdk1 is sufficient to drive the mammalian cell cycleNature, 2007
- Insights for the development of specific kinase inhibitors by targeted structural genomicsDrug Discovery Today, 2007
- Mice thrive without Cdk4 and Cdk2Molecular Oncology, 2007
- Requirements for Cdk7 in the Assembly of Cdk1/Cyclin B and Activation of Cdk2 Revealed by Chemical Genetics in Human CellsMolecular Cell, 2007
- Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemiaBlood, 2006
- Combined Depletion of Cell Cycle and Transcriptional Cyclin-Dependent Kinase Activities Induces Apoptosis in Cancer CellsCancer Research, 2006
- Combined Loss of Cdk2 and Cdk4 Results in Embryonic Lethality and Rb HypophosphorylationDevelopmental Cell, 2006
- CDK/GSK-3 Inhibitors as a New Approach for the Treatment of Proliferative Renal DiseasesDrug News & Perspectives, 2006
- The In vitro and In vivo Effects of JNJ-7706621: A Dual Inhibitor of Cyclin-Dependent Kinases and Aurora KinasesCancer Research, 2005
- Substituted aminobenzimidazole pyrimidines as cyclin-dependent kinase inhibitorsBioorganic & Medicinal Chemistry Letters, 2005